Skip to main content

Ontinua ER FDA Approval Status

FDA Approved: No
Brand name: Ontinua ER
Generic name: arbaclofen
Dosage form: Extended-Release Tablets
Company: Osmotica Pharmaceuticals plc
Treatment for: Spasticity, Multiple Sclerosis

Ontinua ER (arbaclofen) is a prodrug of R-baclofen in devleopment for the treatment of spasticity associated with multiple sclerosis.

Development timeline for Ontinua ER

Sep 28, 2015Osmotica Announces FDA Acceptance of Filing for Ontinua ER for Alleviation of Spasticity Resulting from Multiple Sclerosis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.